Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(04): 143-146
DOI: 10.4103/sajc.sajc_202_17
Letter to the Editor

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer

Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Swaratika Majumdar
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vijay Patil
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vaishakhi Trivedi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Anuradha Chougule
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations Source of Support: Nill.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629-40.